Hudson Bay Capital Management
CMPX icon

Hudson Bay Capital Management’s Compass Therapeutics CMPX Stock Holding History

Hudson Bay Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-134,000
Closed -$255K – 1424
2025
Q1 		$255K Buy
+134,000
New +$356K ﹤0.01% 1114

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management's CMPX Position: Q1 2023 in Review

Hudson Bay Capital Management sold out of Compass Therapeutics (CMPX) in Q1 2023, closing a stake of 311,500 shares — an estimated $1.49M sold.

Hudson Bay Capital Management first reported a position in CMPX in Q4 2022 and held it in 1 quarter. The position peaked at $1.49M in Q4 2022. 72 funds tracked by Wall St. Rank hold CMPX as of Q1 2023.

  • Hudson Bay Capital Management reported no remaining Compass Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 311,500 Compass Therapeutics shares in Q1 2023, an estimated $1.49M.
  • Hudson Bay Capital Management first reported a position in Compass Therapeutics in Q4 2022 and held it in 1 quarter.
  • Hudson Bay Capital Management's Compass Therapeutics position peaked at $1.49M in Q4 2022.
  • 72 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2023.

Based on Hudson Bay Capital Management's 13F filing for Q1 2023, filed 15 May 2023.